See the Complete Picture.

Browser Extension

Tuesday, June 3, 2025

US Edition

Subscribe Login

Israel-Hamas Conflict

Artificial Intelligence

Natural Disasters

Eyewire+ image

News from Eyewire+

Topics Most Covered by Eyewire+

Artificial Intelligence

Sources Covering Similar Topics

ophthalmologytimes.com

optometrytimes.com

modernretina.com

ophthalmologytimes.com

optometrytimes.com

modernretina.com

Suggest a source

Looking for a source we don't already have? Suggest one here.

News Home Page Local News Blindspot Feed International Covid-19

International North America South America Europe Asia Australia Africa

Trending Internationally Artificial Intelligence Social Media Natural Disasters Unemployment Stock Markets

Trending in U.S.Israel-Hamas Conflict US Economy Baseball Stock Markets Donald Trump

Trending in U.K.Israel-Hamas Conflict Manchester United Premier League UK Economy UK Politics

Trending Topics

Artificial Intelligence Social Media Natural Disasters Unemployment Israel-Hamas Conflict

CompanyAbout History Mission Blog Testimonials Group Subscriptions Subscribe Gift Free Trial Careers Affiliates

HelpHelp Center FAQ Contact Us For Educators/Libraries Media Bias Ratings Ownership and Factuality Ratings Referral Code News Sources Topics

ToolsApp Browser Extension Daily Newsletter Blindspot Report Newsletter Burst Your Bubble Newsletter Timelines

Gift Privacy Policy Manage Cookies Terms and Conditions

© 2025 Snapwise Inc

Search Blindspot Local

News from Eyewire+

Stay current with all the latest and breaking news from Eyewire+. Compare headlines and media bias behind news outlets on stories breaking today.

In total, 118 have been published by Eyewire+ which Ground News has aggregated in the past 3 months.

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Stay current with all the latest and breaking news from Eyewire+. Compare headlines and media bias behind news outlets on stories breaking today. In total, 118 have been published by Eyewire+ which Ground News has aggregated in the past 3 months.

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

Alcon Announces FDA Approval of TRYPTYR (Acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

United States · United States

Alcon Announces FDA Approval of TRYPTYR (Acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

67% Center coverage: 3 sources

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates […]See the Story

EssilorLuxottica Expands Med-Tech Strategy With Acquisition of Ophthalmology Platform Optegra

EssilorLuxottica Expands Med-Tech Strategy With Acquisition of Ophthalmology Platform Optegra

Coverage: 2 sources

The agreement inked with private equity MidEuropa will allow the eyewear group to enhance its capabilities in comprehensive eyecare, advanced diagnostics, and surgical treatments.See the Story

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine ...

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine ...

100% Center coverage: 1 sources

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placeboPhase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a…See the Story

Roche’s Susvimo Approved by FDA for Diabetic Retinopathy

Roche’s Susvimo Approved by FDA for Diabetic Retinopathy

100% Right coverage: 1 sources

Breakthrough eye implant treats diabetic retinopathy with just 2 treatments yearly vs monthly injections. See how this FDA-approved device transforms patient care.United States · United States See the Story

Unlocking the genetics of blindness: New hope for sufferers of inherited retinal diseases

Unlocking the genetics of blindness: New hope for sufferers of inherited retinal diseases

100% Center coverage: 1 sources

Researchers at the University of Oklahoma are advancing the fight against inherited retinal diseases (IRDs) with new genetic research that aims to improve diagnoses and lay the groundwork for future therapies.DNA · Norman See the Story

HIV Drug Shows Potential as Oral Treatment for Diabetic Macular Edema

HIV Drug Shows Potential as Oral Treatment for Diabetic Macular Edema

The results show promise, as vision typically improves the most during the first 4 weeks, but with lamivudine, vision continued to improve in the following 4 weeks.Maryland · Maryland See the Story

Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMD

Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMD

Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year after the study was conceptualized reflects an extraordinary pace of execution and underscores our commitment to advancing innovation for patients with wet AMD,” Pravin U. Dugel, MD, Executi…AMD · United States Read Article

Pangaea Data Secures Investment from Topcon Healthcare to Scale AI Platform

Pangaea Data Secures Investment from Topcon Healthcare to Scale AI Platform

Pangaea Data announced an investment from Topcon Healthcare to accelerate the application of Pangaea’s AI platform, which aims to address care gaps in eye health and systemic disease. Financial terms of the deal were not disclosed. Pangaea Data’s platform automatically analyzes structured and unstructured patient records against clinical guidelines, emulating a clinician’s manual review, to uncover patients who meet diagnostic or treatment crite…Artificial Intelligence · United States Read Article

EyePoint Completes Enrollment for Phase 3 LUGANO Trial of DURAVYU in Wet AMD

EyePoint Completes Enrollment for Phase 3 LUGANO Trial of DURAVYU in Wet AMD

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.AMD · Lugano See the Story

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

100% Center coverage: 1 sources

Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan Milestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025 Extends Nicox's cash runway until the end of 2…Japan · Japan See the Story

[Opinion] Bayer’s Eylea Set for Longer Treatment Intervals to Challenge Roche’s Vabysmo - Pharmaceutical Technology

[Opinion] Bayer’s Eylea Set for Longer Treatment Intervals to Challenge Roche’s Vabysmo - Pharmaceutical Technology

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea 8mg.Opinion · China See the Story

Breaking News Topics Related to Eyewire+

AMD

Salt Lake County

California, United States

United States

Maryland

Canada

Similar News Topics

Pharmacy Times

stocktitan.net

Pharmaceutical-technology.com

optometrytimes.com

Endpoints News